Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial [NCT00242489]

BACKGROUND: The aim of this study was to evaluate the long-term efficacy and tolerability of etoricoxib, a COX-2 selective inhibitor, in osteoarthritis (OA) patients. METHODS: A double-blind, randomized, multicenter study was conducted in 617 patients with OA of the knee. The base study was 14 weeks...

Descripción completa

Detalles Bibliográficos
Autores principales: Curtis, Sean P, Bockow, Barry, Fisher, Chester, Olaleye, Joseph, Compton, Amy, Ko, Amy T, Reicin, Alise S
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1327669/
https://www.ncbi.nlm.nih.gov/pubmed/16321158
http://dx.doi.org/10.1186/1471-2474-6-58

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1327669/
https://www.ncbi.nlm.nih.gov/pubmed/16321158
http://dx.doi.org/10.1186/1471-2474-6-58

Ejemplares similares